Genmab A/S (NASDAQ:GMAB) Upgraded by The Goldman Sachs Group to “Buy” Rating

The Goldman Sachs Group upgraded shares of Genmab A/S (NASDAQ:GMAB) from a neutral rating to a buy rating in a research note released on Wednesday, MarketBeat.com reports.

A number of other equities research analysts have also recently commented on the company. Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a research note on Wednesday, March 25th. Jefferies Financial Group initiated coverage on Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price target for the company. Guggenheim decreased their price target on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Wolfe Research initiated coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price target for the company. Finally, Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.36.

Genmab A/S Trading Up 2.3%

Genmab A/S stock opened at $27.69 on Wednesday. The stock has a 50-day moving average of $27.79 and a two-hundred day moving average of $30.29. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. Genmab A/S has a one year low of $18.89 and a one year high of $35.43. The stock has a market cap of $17.79 billion, a PE ratio of 17.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. On average, research analysts anticipate that Genmab A/S will post 1.17 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the last quarter. Sei Investments Co. grew its stake in Genmab A/S by 4.2% during the 2nd quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares during the last quarter. Squarepoint Ops LLC grew its stake in Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Quantinno Capital Management LP grew its stake in Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after purchasing an additional 62,226 shares during the last quarter. Finally, Raymond James Financial Inc. grew its stake in Genmab A/S by 48.1% during the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock valued at $643,000 after purchasing an additional 10,113 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.